Commentary - Using meta-analysis to explain the diversity of results in genetic studies of late-onset Alzheimer's disease and to identify high-risk subgroups

被引:52
作者
Lehmann, DJ
Williams, J
McBroom, J
Smith, AD
机构
[1] Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England
[2] Radcliffe Infirm, OPTIMA, Oxford OX2 6HE, England
[3] Univ Oxford, Dept Stat, Oxford OX1 3TG, England
关键词
apolipoprotein E epsilon 4; butyrylcholinesterase K; meta-analysis; association; case-control; susceptibility;
D O I
10.1016/S0306-4522(01)00464-X
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
In late-onset Alzheimer's disease, there is a puzzling inconsistency between the findings of case-control studies of most proposed risk genes, except apolipoprotein E epsilon4. This inconsistency may stem from the failure to define the genetic and non-genetic interactions that affect the disease association of each particular susceptibility gene. Such interactions will limit the influence of the gene to a 'relevant subset' of vulnerable people, The relevant subsets for many risk genes will be narrow, compared to that of apolipoprotein E epsilon4. Studies may therefore miss the association or even suggest that a risk gene is protective. In these circumstances, the precise composition of a cohort is critical and defining the relevant subset is crucial. We illustrate how such definition may be achieved through meta-analysis. We take as an example the butyrylcholinesterase K variant, whose association with Alzheimer's disease may now be provisionally defined. This analysis leads to the identification of it potentially high-risk group: over 75 year old male carriers of both apolipoprotein E epsilon4 and butyrylcholinesterase K variant. (C) 2001 IBRO. Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:541 / 554
页数:14
相关论文
共 104 条
[1]   Genetic polymorphisms and disease [J].
Altshuler, D ;
Kruglyak, L ;
Lander, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (22) :1626-1626
[2]  
American Psychiatric Association, 1987, DSM 3 R DIAGNOSTIC S, V3rd
[3]  
[Anonymous], NEUROBIOL AGING
[4]  
ARMITAGE P, 1983, STAT METHODS MED RES
[5]  
Bergem ALM, 1997, ARCH GEN PSYCHIAT, V54, P264
[6]   Candidate genes showing no evidence for association or linkage with Alzheimer's disease using family-based methodologies [J].
Bertram, L ;
Blacker, D ;
Crystal, A ;
Mullin, K ;
Keeney, D ;
Jones, J ;
Basu, S ;
Yhu, S ;
Guénette, S ;
McInnis, M ;
Go, R ;
Tanzi, R .
EXPERIMENTAL GERONTOLOGY, 2000, 35 (9-10) :1353-1361
[7]   APO-E-ALLELE FREQUENCIES IN ALZHEIMERS-DISEASE, LEWY BODY DEMENTIA, ALZHEIMERS-DISEASE WITH CEREBROVASCULAR-DISEASE AND VASCULAR DEMENTIA [J].
BETARD, C ;
ROBITAILLE, Y ;
GEE, M ;
TIBERGHIEN, D ;
LARRIVEE, D ;
ROY, P ;
MORTIMER, JA ;
GAUVREAU, D .
NEUROREPORT, 1994, 5 (15) :1893-1896
[8]   Analysis of the butyrylcholinesterase gene and nearby chromosome 3 markers in Alzheimer disease [J].
Brindle, N ;
Song, Y ;
Rogaeva, E ;
Premkumar, S ;
Levesque, G ;
Yu, G ;
Ikeda, M ;
Nishimura, M ;
Paterson, A ;
Sorbi, S ;
Duara, R ;
Farrer, L ;
St George-Hyslop, P .
HUMAN MOLECULAR GENETICS, 1998, 7 (05) :933-935
[9]   A pharmacogenomic approach to Alzheimer's disease [J].
Cacabelos, R ;
Alvarez, A ;
Fernández-Novoa, L ;
Lombardi, VRM .
ACTA NEUROLOGICA SCANDINAVICA, 2000, 102 :12-19
[10]   APOLIPOPROTEIN-E, EPSILON-4 ALLELE AS A MAJOR RISK FACTOR FOR SPORADIC EARLY AND LATE-ONSET FORMS OF ALZHEIMERS-DISEASE - ANALYSIS OF THE 19Q13.2 CHROMOSOMAL REGION [J].
CHARTIERHARLIN, MC ;
PARFITT, M ;
LEGRAIN, S ;
PEREZTUR, J ;
BROUSSEAU, T ;
EVANS, A ;
BERR, C ;
VIDAL, O ;
ROQUES, P ;
GOURLET, V ;
FRUCHART, JC ;
DELACOURTE, A ;
ROSSOR, M ;
AMOUYEL, P .
HUMAN MOLECULAR GENETICS, 1994, 3 (04) :569-574